Navigating Immunotherapies: IVIG vs. Plasmapheresis for Autoimmune POTS and Small Fiber Neuropathy

Living with a chronic condition like Postural Orthostatic Tachycardia Syndrome (POTS) or Small Fiber Neuropathy (SFN) can be incredibly challenging, especially when an autoimmune component is suspected. The journey to finding effective treatments often involves exploring various options, and for some, immunotherapies like Intravenous Immunoglobulin (IVIG) and Plasmapheresis (also known as Therapeutic Plasma Exchange or TPE) emerge as potential avenues. These treatments aim to modulate the immune system, which is believed to be overactive or misdirected in autoimmune conditions.

This article will break down what IVIG and Plasmapheresis are, when they might be considered, the current evidence supporting their use, potential risks, and the practical challenges patients often face in accessing them. Our goal is to provide clear, empowering information to help you understand these complex treatments.

What Are IVIG and Plasmapheresis?

Intravenous Immunoglobulin (IVIG)

IVIG is a product made from human plasma that contains antibodies (immunoglobulins) from thousands of healthy donors. When administered intravenously, these antibodies can help regulate an overactive immune system. It's thought to work by neutralizing harmful autoantibodies, blocking inflammatory processes, and modulating immune cell function. IVIG is FDA-approved for several immune-mediated neurological disorders, such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

Plasmapheresis (Therapeutic Plasma Exchange - TPE)

Plasmapheresis is a medical procedure that involves removing a patient's blood, separating the plasma (the liquid component of blood that contains antibodies and other proteins) from the blood cells, and then returning the blood cells to the patient along with a replacement fluid (like albumin or fresh frozen plasma). The primary goal of plasmapheresis in autoimmune conditions is to remove harmful autoantibodies or other immune factors circulating in the plasma that are contributing to the disease.

When Are These Immunotherapies Considered?

Both IVIG and Plasmapheresis are generally considered for patients with autoimmune POTS and SFN who have not responded adequately to conventional treatments. The decision to pursue these therapies is complex and typically involves:

• Clear evidence of autoimmunity: This might include positive autoimmune markers, a history of an acute illness preceding symptom onset, or specific antibody findings (though a single causative antibody for autoimmune POTS has not been definitively identified).
• Significant disability: Patients usually experience severe and debilitating symptoms that significantly impact their quality of life.
• Diagnosis of Small Fiber Neuropathy: SFN is often a comorbidity with autoimmune POTS, and its presence can strengthen the rationale for immunotherapy, especially if nerve biopsy shows reduced epidermal nerve fiber density.
• Exclusion of other causes: Other conditions that can cause similar symptoms (e.g., diabetes, B12 deficiency, heavy alcohol use) must be ruled out.

It's important to note that these treatments are not typically first-line therapies but rather options explored when other approaches have been exhausted or are ineffective.

The Evidence Base: What Does the Research Say?

The research landscape for IVIG and Plasmapheresis in autoimmune POTS and SFN is evolving. While some studies show promise, more large-scale, randomized controlled trials are needed.

IVIG for Autoimmune POTS and SFN

• Promising uncontrolled studies: Previous uncontrolled studies have suggested efficacy of IVIG for SFN associated with autoimmune dysautonomia, POTS, and post-COVID-19 infection. Some reports indicate improvement in approximately 80% of people with SFN.
• Mixed results in controlled trials: However, randomized controlled studies for painful SFN and POTS have not consistently shown significant benefits. This discrepancy might be due to differences in patient selection, IVIG dosing, treatment duration, and outcome measures.
• Retrospective studies: A recent retrospective study (Novak et al., 2026) on high-dose, long-term IVIG therapy for autoimmune autonomic and sensory SFN (ASFN) found beneficial effects, including improved autonomic symptoms and skin biopsy findings. Adverse effects were frequent but generally tolerable.

Plasmapheresis for Autoimmune POTS and SFN

• Case series and anecdotal evidence: Much of the evidence for Plasmapheresis in autoimmune POTS and SFN comes from case series and anecdotal reports. These suggest that TPE can lead to significant functional improvement and reduction in autonomic symptoms, particularly in severe, treatment-refractory cases.
• Mechanism of action: TPE's ability to remove circulating autoantibodies and immune complexes makes it a theoretically appealing treatment for autoimmune conditions. Studies have shown that patients often experience quick symptom improvement after TPE sessions.
• Limited large-scale trials: Similar to IVIG, large-scale randomized controlled trials specifically for autoimmune POTS and SFN are limited, making it challenging to draw definitive conclusions about its widespread efficacy.

Risks and Side Effects

Both IVIG and Plasmapheresis carry potential risks and side effects that patients should be aware of.

IVIG Risks

• Common side effects: These can include headache, fever, chills, muscle aches, fatigue, and nausea, often occurring during or shortly after infusion. These are usually mild and manageable.
• More serious side effects: Rare but serious risks include aseptic meningitis (especially in patients with autonomic dysfunction), kidney problems, blood clots, and allergic reactions. Slowing the infusion rate can often mitigate some of these risks.
• High prevalence of adverse effects: One study noted a 93% prevalence of adverse effects with high-dose IVIG, though most were tolerable.

Plasmapheresis Risks

• Procedure-related risks: These include complications related to venous access (e.g., infection, bleeding, pneumothorax from central line placement), and reactions to replacement fluids.
• Side effects during/after procedure: Patients may experience dizziness, low blood pressure, fatigue, numbness or tingling (due to citrate used as an anticoagulant), and electrolyte imbalances.
• Immunosuppression: By removing antibodies, TPE can temporarily weaken the immune system, increasing the risk of infection.

Access Challenges

Accessing IVIG and Plasmapheresis can be a significant hurdle for patients due to several factors:

• Cost: Both treatments are very expensive, often costing thousands of dollars per session or course of treatment.
• Insurance coverage: Obtaining insurance approval can be difficult, as these therapies are often considered "off-label" for autoimmune POTS and SFN (meaning they are not FDA-approved for these specific conditions). This often requires extensive documentation, appeals, and advocacy.
• Availability of specialized centers: These treatments require specialized medical facilities and trained personnel, which may not be readily available in all geographic areas.
• Physician knowledge and willingness: Not all physicians are familiar with the use of IVIG or Plasmapheresis for autoimmune POTS and SFN, and some may be hesitant to prescribe them due to the lack of widespread randomized controlled trial data.

Practical Takeaways for Patients

If you and your doctor are considering IVIG or Plasmapheresis, here are some practical takeaways:

• Advocate for yourself: Be prepared to be your own advocate. Gather all relevant medical records, test results, and a detailed history of your symptoms and previous treatments. This documentation is crucial for insurance appeals and for convincing healthcare providers of the necessity of these treatments.
• Seek out specialists: Look for neurologists, immunologists, or autonomic specialists who have experience treating autoimmune POTS and SFN with immunotherapies. Their expertise can be invaluable in navigating the complexities of diagnosis, treatment, and insurance.
• Understand the commitment: Both treatments involve a significant time commitment for infusions or exchanges, and potentially long-term maintenance. Be prepared for frequent clinic visits and the impact on your daily life.
• Manage expectations: While these treatments can be life-changing for some, they are not a cure-all. It's important to have realistic expectations about potential improvements and to understand that individual responses vary.
• Be aware of side effects: Discuss potential side effects thoroughly with your medical team and know what to look for. Early recognition and management of side effects can improve tolerability.

Comparison Table: IVIG vs. Plasmapheresis

Bottom Line

For individuals with autoimmune POTS and Small Fiber Neuropathy who have exhausted conventional therapies, IVIG and Plasmapheresis offer potential hope by targeting underlying immune dysfunction. While the evidence base continues to grow, particularly for IVIG, these treatments are complex, expensive, and come with their own set of risks and access challenges. Open and honest communication with a knowledgeable healthcare team, coupled with diligent self-advocacy, are paramount for navigating these advanced immunotherapies and determining if they are the right path for your unique journey.

Related Articles

• Autoimmune POTS: Antibodies, Mechanisms, and Immunotherapy Options
• Small Fiber Neuropathy Treatment: IVIG, Medications, and Emerging Therapies
• Small Fiber Neuropathy Symptoms: Burning, Tingling, and Autonomic Features
• POTS Medications: A Complete Guide to All Treatment Options